{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:53:32Z","timestamp":1785430412966,"version":"3.56.0"},"reference-count":36,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kaohsiung Municipal Min-Sheng Hospital","award":["KMSH-11303"],"award-info":[{"award-number":["KMSH-11303"]}]},{"name":"National Science and Technology Council","award":["NSTC 113-2320-B-127-001"],"award-info":[{"award-number":["NSTC 113-2320-B-127-001"]}]},{"name":"National Science and Technology Council","award":["NSTC 112-2321-B-037-007"],"award-info":[{"award-number":["NSTC 112-2321-B-037-007"]}]},{"award":["NSTC 113-2320-B-127-001"],"award-info":[{"award-number":["NSTC 113-2320-B-127-001"]}],"id":[{"id":"https:\/\/ror.org\/02kv4zf79","id-type":"ROR","asserted-by":"publisher"}]},{"award":["NSTC 112-2321-B-037-007"],"award-info":[{"award-number":["NSTC 112-2321-B-037-007"]}],"id":[{"id":"https:\/\/ror.org\/02kv4zf79","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Ministry of Science and Technology","award":["MOST 111-2320-B-037-020-MY3"],"award-info":[{"award-number":["MOST 111-2320-B-037-020-MY3"]}]},{"award":["MOST 111-2320-B-037-020-MY3"],"award-info":[{"award-number":["MOST 111-2320-B-037-020-MY3"]}],"id":[{"id":"https:\/\/ror.org\/02kv4zf79","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Drug Development and Value Creation Research Center","award":["KMU-TC112A03-3"],"award-info":[{"award-number":["KMU-TC112A03-3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Inflammation can promote aggressive phenotypes in prostate cancer, including enhanced migration\/EMT-like changes and inflammasome-associated cytokine release. Here, we examined whether curcumin modulates these inflammation-driven responses in androgen-independent prostate cancer cells. PC-3 and DU145 cells were treated with curcumin (10 or 25 \u03bcM) or N-acetylcysteine (NAC; 2 mM). Sub-cytotoxic dosing was defined by CCK-8 viability assays. LPS (0.5 \u03bcg\/mL) was used to induce motility-, invasion-, and EMT-associated responses, assessed by wound-healing assay, Matrigel-coated Transwell invasion assay, and RT\u2013qPCR of SNAI1, CDH1, and VIM. Intracellular ROS was quantified by CM-H2DCFDA flow cytometry. Inflammasome-associated and EMT-related protein changes were evaluated under LPS priming (24 h) followed by ATP triggering (5 mM, 1 h), with NLRP3, cleaved caspase-1, cleaved IL-1\u03b2, vimentin, and E-cadherin assessed by immunoblotting and IL-1\u03b2 secretion measured by ELISA. Curcumin at 10\u201325 \u03bcM did not cause overt cytotoxicity and significantly reduced LPS-induced wound closure and invasive activity in both cell lines, accompanied by attenuation of EMT-associated transcriptional changes and a decrease in ROS-positive events. Under LPS priming\/ATP triggering, inflammasome-associated protein signals and IL-1\u03b2 secretion were robustly induced; curcumin suppressed IL-1\u03b2 release and attenuated NLRP3, cleaved caspase-1, and cleaved IL-1\u03b2 signals, while reversing vimentin\/E-cadherin changes. NAC produced similar inhibitory patterns, supporting a redox-linked contribution to these responses. Collectively, curcumin dampens inflammation-driven motility\/invasion, EMT-associated changes, and inflammasome-associated responses in androgen-independent prostate cancer cells.<\/jats:p>","DOI":"10.3390\/cimb48040413","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:53:46Z","timestamp":1776426826000},"page":"413","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Curcumin Attenuates LPS-Induced Migration\/EMT and LPS\/ATP-Associated IL-1\u03b2 Release in Androgen-Independent Prostate Cancer Cells"],"prefix":"10.3390","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0671-7614","authenticated-orcid":false,"given":"Mon-Der","family":"Cho","sequence":"first","affiliation":[{"name":"Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung 807378, Taiwan"},{"name":"Department of Urology, Kaohsiung Municipal Min-Sheng Hospital, Kaohsiung 802511, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Yu","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 824005, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0958-3025","authenticated-orcid":false,"given":"Yu-Ming","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Master Program, College of Pharmacy and Health Care, Tajen University, Pingtung County 907101, Taiwan"},{"name":"Research Center for Precision Environmental Medicine, Kaohsiung Medical University, Kaohsiung 807378, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ying","family":"Li","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Tzu Chi University, Hualien 970374, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4674-3363","authenticated-orcid":false,"given":"Yi-Hong","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Master Program, College of Pharmacy and Health Care, Tajen University, Pingtung County 907101, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2549-4193","authenticated-orcid":false,"given":"Fang-Rong","family":"Chang","sequence":"additional","affiliation":[{"name":"Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung 807378, Taiwan"},{"name":"Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung 804201, Taiwan"},{"name":"Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung 807378, Taiwan"},{"name":"Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807378, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: Planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Belabaci, Z., Mose, L., El-Taji, O., Otmani, Z., Hannouneh, Z.A., Mohamad, I., Zilli, T., Mohamad, O., Pervez, N., and Arafat, W. (2025). Safety and Efficacy of Reduced Dose of Enzalutamide in Patients with Castration-Resistant Prostate Cancer: A Systematic Review. Pharmaceuticals, 18.","DOI":"10.3390\/ph18050732"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist. Updates"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2119568","DOI":"10.1001\/jamanetworkopen.2021.19568","article-title":"Causes of Death among Patients with Metastatic Prostate Cancer in the US from 2000 to 2016","volume":"4","author":"Elmehrath","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101232","DOI":"10.1016\/j.jpha.2025.101232","article-title":"Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistance","volume":"15","author":"Wang","year":"2025","journal-title":"J. Pharm. Anal."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"155379","DOI":"10.1016\/j.prp.2024.155379","article-title":"Toll-like receptor (TLR) 4 is a potent prognostic factor in prostate cancer associated with proliferation and invasion","volume":"260","author":"Takahashi","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/pros.23722","article-title":"Lipopolysaccharide (LPS) enhances prostate cancer metastasis potentially through NF-\u03baB activation and recurrent dexamethasone administration fails to suppress it in vivo","volume":"79","author":"Jain","year":"2019","journal-title":"Prostate"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bahmad, H.F., Jalloul, M., Azar, J., Moubarak, M.M., Samad, T.A., Mukherji, D., Al-Sayegh, M., and Abou-Kheir, W. (2021). Tumor Microenvironment in Prostate Cancer: Toward Identification of Novel Molecular Biomarkers for Diagnosis, Prognosis, and Therapy Development. Front. Genet., 12.","DOI":"10.3389\/fgene.2021.652747"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","article-title":"Guidelines and definitions for research on epithelial\u2013mesenchymal transition","volume":"21","author":"Yang","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Loh, C.Y., Chai, J.Y., Tang, T.F., Wong, W.F., Sethi, G., Shanmugam, M.K., Chong, P.P., and Looi, C.Y. (2019). The e-cadherin and n-cadherin switch in epithelial-to-mesenchymal transition: Signaling, therapeutic implications, and challenges. Cells, 8.","DOI":"10.3390\/cells8101118"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"BSR20211754","DOI":"10.1042\/BSR20211754","article-title":"Epithelial-mesenchymal transition and its transcription factors","volume":"42","author":"Debnath","year":"2022","journal-title":"Biosci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.21037\/tau-21-964","article-title":"Inflammation induced by lipopolysaccharide advanced androgen receptor expression and epithelial-mesenchymal transition progress in prostatitis and prostate cancer","volume":"10","author":"Wang","year":"2021","journal-title":"Transl. Androl. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.12659\/MSM.906857","article-title":"Toll-like receptor 4 (TLR4)\/cyclooxygenase-2 (COX-2) regulates prostate cancer cell proliferation, migration, and invasion by NF-\u03baB activation","volume":"24","author":"Wang","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"106346","DOI":"10.1016\/j.intimp.2020.106346","article-title":"Calcitriol inhibits lipopolysaccharide-induced proliferation, migration and invasion of prostate cancer cells through suppressing STAT3 signal activation","volume":"82","author":"Xing","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17036","DOI":"10.1038\/sigtrans.2017.36","article-title":"Redox regulation in tumor cell epithelial\u2013mesenchymal transition: Molecular basis and therapeutic strategy","volume":"2","author":"Jiang","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s13287-023-03571-6","article-title":"Oxidative stress regulation and related metabolic pathways in epithelial\u2013mesenchymal transition of breast cancer stem cells","volume":"14","author":"Farahzadi","year":"2023","journal-title":"Stem Cell Res. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1478-811X-10-33","article-title":"Role of TLR4\/NADPH oxidase\/ROS-activated p38 MAPK in VCAM-1 expression induced by lipopolysaccharide in human renal mesangial cells","volume":"10","author":"Lee","year":"2012","journal-title":"Cell Commun. Signal."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Xia, F., Li, Y., Deng, L., Ren, R., Ge, B., Liao, Z., Xiang, S., and Zhou, B. (2022). Alisol B 23-Acetate Ameliorates Lipopolysaccharide-Induced Intestinal Barrier Dysfunction by Inhibiting TLR4-NOX1\/ROS Signaling Pathway in Caco-2 Cells. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.911196"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Blevins, H.M., Xu, Y., Biby, S., and Zhang, S. (2022). The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases. Front. Aging Neurosci., 14.","DOI":"10.3389\/fnagi.2022.879021"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lillo, S., and Saleh, M. (2022). Inflammasomes in Cancer Progression and Anti-Tumor Immunity. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.839041"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41419-019-1413-8","article-title":"Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors","volume":"10","author":"Yang","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Sundram, V., Chauhan, S.C., Ebeling, M., and Jaggi, M. (2012). Curcumin attenuates \u03b2-catenin signaling in prostate cancer cells through activation of protein kinase D1. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035368"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12935-024-03483-2","article-title":"Curcumin blunts epithelial-mesenchymal transition to alleviate invasion and metastasis of prostate cancer through the JARID1D demethylation","volume":"24","author":"Xie","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Shahcheraghi, S.H., Salemi, F., Peirovi, N., Ayatollahi, J., Alam, W., Khan, H., and Saso, L. (2022). Nrf2 regulation by curcumin: Molecular aspects for therapeutic prospects. Molecules, 27.","DOI":"10.3390\/molecules27010167"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Cui, J., Li, H., Zhang, T., Lin, F., Chen, M., Zhang, G., and Feng, Z. (2025). Research progress on the mechanism of curcumin anti-oxidative stress based on signaling pathway. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1548073"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Benameur, T., Gaban, S.V.F., Giacomucci, G., Filannino, F.M., Trotta, T., Polito, R., Messina, G., Porro, C., and Panaro, M.A. (2023). The Effects of Curcumin on Inflammasome: Latest Update. Molecules, 28.","DOI":"10.3390\/molecules28020742"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.2147\/JIR.S332943","article-title":"Bacterial lipopolysaccharide augmented malignant transformation and promoted the stemness in prostate cancer epithelial cells","volume":"14","author":"Tang","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_29","first-page":"1147","article-title":"Periostin induces epithelial-to-mesenchymal transition via the integrin \u03b15\u03b21\/TWIST-2 axis in cholangiocarcinoma","volume":"43","author":"Sonongbua","year":"2020","journal-title":"Oncol. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100773","DOI":"10.1016\/j.tranon.2020.100773","article-title":"Epithelial-Mesenchymal Transition in Cancer: A Historical Overview","volume":"13","author":"Ribatti","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Esmaeli, M., and Dehabadi, M.D. (2025). Curcumin in prostate cancer: A systematic review of molecular mechanisms and nanoformulated therapeutic strategies. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-15152-2"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Yu, J.F., Tang, R., and Li, J.Y. (2022). Identification of pyroptosis-related lncRNA signature and AC005253.1 as a pyroptosis-related oncogene in prostate cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.991165"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1038\/s41598-017-04286-4","article-title":"Expression analysis of inflammasome sensors and implication of NLRP12 inflammasome in prostate cancer","volume":"7","author":"Karan","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41420-021-00766-9","article-title":"NLRP3 inflammasome promoted the malignant progression of prostate cancer via the activation of caspase-1","volume":"7","author":"Xu","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2011.09.030","article-title":"Measuring reactive oxygen and nitrogen species with fluorescent probes: Challenges and limitations","volume":"52","author":"Kalyanaraman","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/0118715206297840240510063330","article-title":"Curcumin and its Analogues in Oral Squamous Cell Carcinoma: State-of-the-art and Therapeutic Potential","volume":"25","author":"Schiavoni","year":"2024","journal-title":"Anticancer Agents Med. Chem."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/4\/413\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T04:20:26Z","timestamp":1776572426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/4\/413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["cimb48040413"],"URL":"https:\/\/doi.org\/10.3390\/cimb48040413","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]}}}